User talk:Anypodetos/Archive 3

Archive 1

Archive 2

Archive 3

Archive 4

Archive 5

→

Archive 10

PotatoBot 5's trial

I hope all went well with the trial of the new redirecting function of PotatoBot. I'm looking forward to see the next step (with that Drugbank data i presume). If I could help in the process in some way, feel free to ask! Mikael Häggström (talk) 07:01, 7 January 2011 (UTC)

The trial looks good to me. The results are at Special:Contributions/PotatoBot, but you'll probably know this. Please tell me if you can spot anything. Now for the complete "Merck run" as soon as I have the permission, and then yes, I plan to do the Drugbank data. Cheers, ἀνυπόδητος (talk) 08:11, 7 January 2011 (UTC)

I saw the log, and I think the bot does a really great job. I saw one entry saying: Nizoral: redirects to Ketoconazole#Hair loss benefits instead of Ketoconazole. It might not be necessary to log those that already redirect to subsections of target articles, but, after all, it doesn't harm. Mikael Häggström (talk) 12:01, 11 January 2011 (UTC)

Yes, there are a few unnecessary log entries resulting from situations I didn't forsee (like "Argatroban: redirecting to Argatroban failed, page already exists"). Thanks for working on the log! --ἀνυπόδητος (talk) 15:06, 11 January 2011 (UTC)

I'd also like to ask, could PotatoBot possibly create disambiguation pages for red-linked names of combination drugs, such as suggested here? It hasn't reached consensus yet, but when (or if) it does, I hope it could be added to the code as well. Mikael Häggström (talk) 07:14, 15 January 2011 (UTC)

Request for comment

I have proposed the renaming of a category, and wanted to know if you would consider commenting on the proposed renaming over at that link? ---My Core Competency is Competency (talk) 04:43, 8 January 2011 (UTC)

User:Ranatalwar

This editor has copied your userpage to their userpage. Thought you might like to know. --Hammersoft (talk) 22:16, 25 January 2011 (UTC)

Thanks. Strange things happen. --ἀνυπόδητος (talk) 13:39, 26 January 2011 (UTC)

From Ranatalwar

removed..

--Ranatalwar (talk) 14:34, 26 January 2011 (UTC)sorry for that i was just cheking the codes to create such page.

Help please

can you help me to restore one article as i am new to wiki.

i Will give you all details.

If you have time please do it.

http://en.wikipedia.org/wiki/User:KuwarOnline/Taj

references as i told one more user few months ago; might help:

Please see

http://apnnews.com/2010/12/23/taj-pharmaceuticals-bags-us-fda-approval-for-generic-topiramate-tablets/ —Preceding unsigned comment added by 59.164.17.195 (talk) 12:57, 25 December 2010 (UTC)

       Thanks for reference, can I get few more say 2-3 reference, then I think I will be able to restore that article. KuwarOnline Talk 18:52, 28 December 2010 (UTC)

More Links

http://www.prlog.org/11183549-major-fda-approval-for-indian-pharmaceuticals-company.html http://www.medindia.net/buy_n_sell/pharm_industry/taj-pharmaceuticals-ltd-Mumbai-Maharashtra-6496-1.htm

405 brands known in India http://www.google.co.in/#hl=en&biw=1024&bih=552&q=site%3Adrugsupdate.com+Taj+Pharma&fp=9af714dd4ddc1fb2 —Preceding unsigned comment added by 59.165.0.172 (talk) 16:31, 30 December 2010 (UTC)

http://www.pharmaage.com/2010/12/28/taj-pharma-bags-fda-nod-for-topiramate/ —Preceding unsigned comment added by 59.165.0.172 (talk) 13:25, 3 January 2011 (UTC)

http://worldprwire.posterous.com/govt-plans-policy-options-to-boost-pharma —Preceding unsigned comment added by 59.165.0.172 (talk) 13:34, 3 January 2011 (UTC)

   Thanks for links I will take up this article once I complete my current task. please provide as much as reference u have. Thanks KuwarOnline Talk 13:49, 3 January 2011 (UTC)

Thank you for reply

This reg=ference is a book: The Pharmacist 2008 Page 5 Link: http://books.google.co.in/books?id=iUFEfBNoEBwC&pg=PA5&dq=Taj+Pharmaceuticals&hl=en&ei=GHgjTeaDHIXYrQfStZ3GCw&sa=X&oi=book_result&ct=result&resnum=1&ved=0CCoQ6AEwAA#v=onepage&q=Taj%20Pharmaceuticals&f=false

http://www.marketpressrelease.com/Taj-Pharmaceuticals-provides-update-on-Bevacizumab-Avastin-for-metastatic-breast-cancer-1294138391.html

http://www.pharmainfo.net/generic-drug-news/01/01/2011/taj-pharmaceuticals-bags-us-fda-approval-generic-topiramate-tablets-mar

http://www.pharmaage.com/2010/12/28/taj-pharma-bags-fda-nod-for-topiramate/

http://worldprwire.livejournal.com/2195310.html

http://www.marketpressrelease.com/The-Pharma-Market-Switzerland-How-Will-the-Governments-Cost-Containment-Plans-Affect-the-Generics-1294058202.html

http://www.indianmirror.com/submitpress/Taj-Pharmaceuticals-bags-US-FDA-approval-for-generic-Topiramate-Tablets.html — Preceding unsigned comment added by Ranatalwar (talk • contribs) 14:45, 26 January 2011 (UTC)

I'm afraid I won't be able to help you much. I've never created an article about a company and don't know much about this work. The links you listed above seem to be mostly press releases and the like, and probably don't meet the requirements in Wikipedia:Identifying reliable sources. The reasons why this article was deleted in the first place are given in Wikipedia:Articles for deletion/Taj Pharmaceuticals – if the people there are right, the company simply isn't notable, which means that the article shouldn't be re-created.

Re-creation is currently blocked, which indicates that someone tried to place an advertisement for this company on Wikipedia. There should be no adverts here, which is another reason why I'm not sure you should re-create the article.

If you want to edit Wikipedia, I'd suggest starting with less controversial topics to get some practice, and return to Taj Pharmaceuticals once you know a bit more about Wikipedia's requirements for a good article. If, on the other hand, you are only interested in Taj Pharmaceuticals, you should perhaps read Wikipedia:Conflict of interest and reconsider whether Wikipedia is the right place for you.

Sorry I have no better news for you. Feel free to contact me again if anything is unclear. Thanks, ἀνυπόδητος (talk) 15:18, 26 January 2011 (UTC)

thank you — Preceding unsigned comment added by Ranatalwar (talk • contribs) 15:24, 26 January 2011 (UTC)

from RANATALWAR

Hello can you guide me how to add articles so that people open it more.

And also some tags how to make it attractive.

And also how to unblock request if some websites are blocked.

I liked your user page.. I am learning how to create it.

I am so happy that now i can fulfill my hobby of writing.

you have indeed done a great contribution to wiki.

I want to do the same.. please fell free to guide me any time.

--Ranatalwar (talk) 00:39, 27 January 2011 (UTC)

To make more people reading an article, it is best to add links to it from other articles. Be careful only to introduce relevant links, such as from a medication to the company that invented or sells it. Adding links to only remotely related articles (such as, say, a link from ACE inhibitor to a company that produces an ACE inhibitor) is considered spamming and will probably be removed.

To make an article attractive, avoid spelling errors and grammatical mistakes, and try to use good prose that is easy to read. Avoid hard words if possible, or link them to their articles so that people can find out what they mean. Look at some of the articles listed at Wikipedia:Good articles to get an idea of a good layout. When you edit an article, look back at it after a few days to see if someone has corrected your edit, and why. I found this practice can teach a lot about writing good articles.

If by a website that is blocked you mean a Wikipedia article: If you only want to edit such an article once (for example to correct a typo or add a sentence), ask on the article's talk page for an administrator to do the edit. Add {{Edit protected}} (including the {{}}) to your request to attract an administrator's attention. If you want an article completely unprotected, use the page Wikipedia:Requests for page protection, but be prepared: You will have to give good reasons why you think that anyone should be able to edit that article again.

Thanks for your praise, and feel free to contact me again. Cheers, ἀνυπόδητος (talk) 13:27, 27 January 2011 (UTC)

/* hello */

thank you for guidence ! you are indeed a good person.

I have made my user page Please have a look and correct it if any mistakes.

I was just wondering If you could help in adding an image to a recent article which i have created.

i will give you links:

http://en.wikipedia.org/wiki/Ranvir_Kumar_Singh

image link of person: http://postimage.org/image/1krrs3og4/

I dont really know how image is added and works.

If you will do it once i can learn from.

If you are too busy its fine.

--Ranatalwar (talk) 14:58, 27 January 2011 (UTC)

Do you know who owns that picture? In other words, is it copyrighted? If yes, use on Wikipedia is unfortunately prohibited by law. Anyway, I'll try and have a look at the article when time allows.

Your user page looks nice. Is your native language really Swedish, although you were born in India? You've had an interesting life :-) And (I hope I don't sound impolite) are you sure that your level of English is "professional"? That's rather a high standard (like journalists and scientists who publish in journals), and I can spot a few typos/grammatical mistakes on your user page. Perhaps you were just distracted from writing. --ἀνυπόδητος (talk) 15:50, 27 January 2011 (UTC)

Hello

Hello this is the same person.

We had a little talk if i remember

I was wondering if you can comment and see if my article can be saved.

Please see:

http://en.wikipedia.org/wiki/Ranvir_Kumar_Singh

I wanted to ask r u admin

Kindly just wanted to know your comments on the same.

I know there is lot to add but i can only do my best if it does not get deleted.

Thank you--Ranatalwar (talk) 17:15, 28 January 2011 (UTC)

No, I'm not an admin. And looking at the deletion discussion, I'm afraid I can't do anything to save the article. Anyway, I've just noticed you got blocked for sock puppetry. --ἀνυπόδητος (talk) 15:20, 1 February 2011 (UTC)

Crikey

I've just noticed that Nomenclature of monoclonal antibodies has been on WP:GAN since November! I presume you are still interested in a review.

I'm actually wondering why the article was ever split off from monoclonal antibody, because it is fairly short compared to many other articles submitted for GA. Furthermore, the "prefix" section is extremely short, and I was wondering if it might not benefit from either expansion or merging. JFW | T@lk 07:18, 4 February 2011 (UTC)

Of course I'm interested! Was it really split from monoclonal antibody (see [1], [2])?

Regarding the "Prefix" section, I don't think it can be expanded – the prefixes really don't mean anything. Merging isn't a good solution either: As it is, every part of the name has its section (except for the stem -mab). Tagging the two "Prefix" sentences to another section would make them harder to find and result in an a somewhat incongruent header like "Substem for target, and prefix". I've (reluctantly) been thinking of this section as a case of IAR, but I'm open to suggestions, of course. --ἀνυπόδητος (talk) 11:00, 4 February 2011 (UTC)

Have just left some comments. Looking forward to your responses. JFW | T@lk 23:43, 10 February 2011 (UTC)

Congratulations on the GA, and commendations on your patience while it was sitting at GAN unreviewed. JFW | T@lk 22:37, 21 February 2011 (UTC)

File:Rhodocene dimerisation.PNG

Hi... As you may recall, you vectorised the image File:Rhodocene dimerisation.PNG for me for the rhodocene FAC. Nergaal, one of the editors who has commented on the FAC, has noted a mistake. The fused Cp's should have the H in the "endo" position (i.e. H is inside, the other Cp on the outside). So, for the cyclopentadiene on the left, there should be an "up" bond (currently occupied by the second cyclopentadiene) to H and a down bond to the second cyclopentadiene. For the cyclopentadiene on the right, the bond incoming from above should come from the first cyclopentadiene and there should be a bond to H shown pointing diagonally "down". Does this make sense? If so, would you be able to make the necessary corrections? Many Thanks. EdChem (talk) 09:10, 6 February 2011 (UTC)

If I got you right, it should be corrected now. I also added the Hs for clarity. Please tell me if I made it worse. --ἀνυπόδητος (talk) 09:29, 6 February 2011 (UTC)

I was hoping you would add the H's - it's just what I wanted. Thanks.  :) EdChem (talk) 11:00, 6 February 2011 (UTC)

More assistance please

Hi Anypodetos... Thanks again for fixing the dimerisation picture so fast. I was wondering if you would be willing to vectorise another synthesis for me? I have just uploaded File:Synthesis of cation of ((C5tBu3H2)Rh(C5H5))BF4.PNG. As you can see, I have pieced it together from various sources so the fonts are different sizes and inconsistent, different formats, etc. If you could do a vectorised version that would be great, making the following corrections:

• the reagants in the first step (1. [(C₂H₄)₂RhCl]₂ and 2. TlC₅H₅) should have subscripts and be presented in the same font and size as other 'over arrow' pieces of text
• the ^tBu symbols in all the structures should be consistent, ideally with superscripted and italicised t's
• I don't much care how the vinylcyclopropene is drawn; it needn't be at the odd angle it is in the diagram I modified
• the equilibrium should use actually equilibrium arrows

I hope all this makes sense. Thanks again. EdChem (talk) 12:43, 6 February 2011 (UTC)

I'll give it a try. Cheers, ἀνυπόδητος (talk) 12:46, 6 February 2011 (UTC)

[3] Fantastic, thanks. EdChem (talk) 14:25, 6 February 2011 (UTC)

My pleasure :-) ἀνυπόδητος (talk) 14:27, 6 February 2011 (UTC)

Yet More Assistance

Hi again, Anypodetos... I think I have (finally) finished everything relating to the text of rhodocene (subject to more comments at FAC), and in the process I have added two more images that would benefit from being vectorised. They are File:Bi- and ter-metallocenes containing rhodocenyl groups.PNG and File:Synthesis of 1-cobaltocenyl-1'-rhodocenylferrocene cation.PNG. Would you mind producing two more of your lovely clean images from my quick-and-dirty don't-have-the-right-software versions? Many many thanks. EdChem (talk) 04:19, 7 February 2011 (UTC)

No problem. I'm not sure I'll have the time today, but I will do it over the next few days. --ἀνυπόδητος (talk) 09:25, 7 February 2011 (UTC)

Shouldn't the reaction arrows in File:Synthesis of 1-cobaltocenyl-1'-rhodocenylferrocene cation.PNG have 2 Li⁺, 2 (C₆H₅)₃C⁺ etc.?

I don't see why they need to be stoichiometrically accurate; the earlier diagram for the 1,2,3-tri-tert-butylrhodocenium cation was not. However, if you strongly feel they should be included I have no great objection. Cheers. EdChem (talk) 13:05, 7 February 2011 (UTC)

 Done. Never mind, I'm just used to being stoichiometrically correct from school. Please tell me if you spot factual errors, rendering problems or anything else you don't like in any of the images. --ἀνυπόδητος (talk) 19:44, 8 February 2011 (UTC)

Thanks. EdChem (talk) 05:26, 9 February 2011 (UTC)

Chemistry Star

		The Chemistry Star
		For all your help with preparing images for the rhodocene article, I award you this Chemistry Star. Well done! EdChem (talk) 05:32, 9 February 2011 (UTC)

If you prefer to display ribbons rather than barnstars, you might be interested to know that a Chemistry Star Ribbon is available, File:Chemistry Star Ribbon.png, as shown at right. EdChem (talk) 05:32, 9 February 2011 (UTC)

Thanks a lot! --ἀνυπόδητος (talk) 08:27, 9 February 2011 (UTC)

Lopinavir/ritonavir

This is an automated message from VWBot. I have performed a web search with the contents of Lopinavir/ritonavir, and it appears to include material copied directly from http://www.mahalo.com/lopinavir.

It is possible that the bot is confused and found similarity where none actually exists. If that is the case, you can remove the tag from the article. The article will be reviewed to determine if there are any copyright issues.

If substantial content is duplicated and it is not public domain or available under a compatible license, it will be deleted. For legal reasons, we cannot accept copyrighted text or images borrowed from other web sites or printed material. You may use such publications as a source of information, but not as a source of sentences. See our copyright policy for further details. (If you own the copyright to the previously published content and wish to donate it, see Wikipedia:Donating copyrighted materials for the procedure.) VWBot (talk) 11:07, 23 February 2011 (UTC)

http://www.mahalo.com/lopinavir is a copy from Lopinavir (which I split), not the other way round. Removed the tag. --ἀνυπόδητος (talk) 11:56, 23 February 2011 (UTC)

Would you mind...

... doing another run with the PotatoBot in redirecting trade names? Mikael Häggström (talk) 18:47, 4 March 2011 (UTC)

Of course I will. I can't give you an exact date, but I'll work on it. Cheers --ἀνυπόδητος (talk) 19:37, 6 March 2011 (UTC)

Running. --ἀνυπόδητος (talk) 11:16, 14 March 2011 (UTC)

Thanks! Mikael Häggström (talk) 15:58, 14 March 2011 (UTC)

...and it seems like it's time for another run now. Mikael Häggström (talk) 15:12, 28 March 2011 (UTC)

Great work on PIE

Hi! I just stumbled across your profile coming from the PIE root, and I have to say you did an amazing job on those PIE linguistics articles. Regards --Codrin.B (talk) 01:25, 10 March 2011 (UTC)

Thank you! Much appreciated. --ἀνυπόδητος (talk) 09:35, 10 March 2011 (UTC)

Paricalcitol

Hey mate:

I'm sorry I didn't realize you had changed the Paricalcitol page back to the original version. Earlier, I accidentally pressed save too early before I was finished. I revised the page again, but if you feel it was better the original way, I won't try to change it again.

Sorry for the confusion, I'm pretty new to this... —Preceding unsigned comment added by 98.239.143.131 (talk) 21:05, 16 March 2011 (UTC)

No problem at all. In fact, good of you to catch the difference between ergo- and cholecalciferol. I didn't realise that paricalcitol was a D₂ analogue because it doesn't make a pharmacological difference; but of course it's a different chemical. I'll try and get rid of some of the long chemical names in the lead without sacrificing accuracy. (It took me about a minute to realise that 1,25-dihydroxyergocalciferol is simply the D₂ analogue of calcitriol...) Cheers, ἀνυπόδητος (talk) 08:56, 17 March 2011 (UTC)

DYK for Icodextrin

—HJ Mitchell | Penny for your thoughts? 00:03, 20 March 2011 (UTC)

Redirect of brand names to generics?

Was a bot every made to do this? Uptodate / Lexicomp has a great database brand names to generic names.--Doc James (talk · contribs · email) 04:09, 26 March 2011 (UTC)

Been answered :-) --Doc James (talk · contribs · email) 05:49, 26 March 2011 (UTC)

Wondering if I could get your comments

[4] --Doc James (talk · contribs · email) 05:54, 26 March 2011 (UTC)

 Done --ἀνυπόδητος (talk) 09:50, 26 March 2011 (UTC)

Re: P-I-E verb

Because other parts-of-speech pages (English verbs, German nouns, etc.) are in the plural. CJ Miller ^[T]/_[C] 20:02, 30 March 2011 (UTC)

OK, thanks. --ἀνυπόδητος (talk) 08:52, 31 March 2011 (UTC)

Another PotatoBot run?

When you have time, I hope you could make some more trade name redirects by PotatoBot. I'd be grateful. Cheers! Mikael Häggström (talk) 06:27, 1 April 2011 (UTC)

Sorry for not responding to your last message. I'll run the bot this weekend or on Monday. --ἀνυπόδητος (talk) 07:17, 1 April 2011 (UTC)

Great. Mikael Häggström (talk) 10:05, 1 April 2011 (UTC)

 Done --ἀνυπόδητος (talk) 11:10, 4 April 2011 (UTC)

Ocreotide

I do not understand why you removed citations in the article ocreotide. Ocreotide can cause diabetes (it was not written, (high glucose level is not excatly diabetes), it can also cause hypotyroidism but I do not see where it was written. According to some study on rats, it can cause also erectile disfunction, you removed this too. I hope we will find an agreement. I also think that the sources in german should not be used in wikipedia.en, anyway I did not delete them. Bye —Preceding unsigned comment added by Moscone (talk • contribs) 18:14, 22 May 2011 (UTC)

Hi! Thank you for your message. Let me explain my reasoning:

I don't have access to the full text of this article, but from the abstract it seems that the study found "reduced leg glucose uptake" and a "hyperglycaemic effect". Even if all eight subjects developed diabetes, the sentence in Octreotide now is wrong in saying "Most frequent adverse effects (more than 10% of patients) are ... diabetes mellitus...".

As far as I know, hypothyroidism is the same as hypothyreosis which is mentioned in the following sentence. Please correct me if I am mistaken.

A study in rats, conducted about 13 years ago, does not say much about erectile dysfunction in humans, let alone support the claim it occurs in more than 10% of patients. Unless I missed something, the clinical trials on which the approval of octreotide is based found no (or few) cases of ED.

Regarding the German language references: I agree that English ones would be preferable, but I don't have access to relevant English reliable sources. If you object, you should replace the references with English ones rather than delete.

Looking forward to hearing your thoughts, ἀνυπόδητος (talk) 20:43, 22 May 2011 (UTC)

Ok, I understand. Is it possible to write these side effects as less frequent (<10%)? I guess that hair loss is more frequent than 10%, there are several studies that link hair loss to ocreotide, can I use the studies that I cited? Thanx --Moscone (talk) 08:09, 23 May 2011 (UTC)

Well, there is no exact rule for which side effects to state. The relevant style guide, WP:MOSMED#Drugs and medications, says "Extract the pertinent information rather than just dumping low-level facts in a big list." which I'd say means add (1) very common and (2) very severe side effects.

About hair loss: The article already says "Data on the frequency of alopecia vary", based on two post-marketing sources which don't really agree on the issue. If you've got really good studies saying octreotide causes hair loss, by all means include them; but please be aware that, say, a study from 10 years ago finding hair loss in 3 of 10 included subjects does not outweigh Phase III and post-marketing data. Cheers, ἀνυπόδητος (talk) 08:27, 23 May 2011 (UTC)

Corepressor

Hi. I was wondering if you could do me a favor. Some time ago, I created the Corepressor article. Just recently, a German interwiki link was added. I then noticed that the German article was nominated for deletion. I tried to fix it myself, but I noticed for good reason that they have become quite annoyed with me ;-) I was wondering if you could take a look at this sandbox version and correct my very bad German. An additional problem is that the subject is inherently complicated and the English version probably needs to be simplified further. If so, please let me know and I will try to make the English version more understandable to a wider audience.

I leaned from the German version that there is a closely related meaning for corepressor pertaining to prokaryotes that was not in the English version. Based on the German version, I updated the English version and I would like to reciprocate. It would be ashame to loose a worthwhile German entry that taught me something. Cheers. Boghog (talk) 19:30, 14 June 2011 (UTC)

I'll have a look at it, but not today. By the way, dewiki is rather deletionist – they tend to delete based on rationales like "Is this supposed to be an article?" –, so don't be disappointed in case we don't succeed. Cheers, ἀνυπόδητος (talk) 20:34, 14 June 2011 (UTC)

Thanks for your reply and no rush. If you think the deletionists will prevail in the end, don't spend too much time on it. Regards. Boghog (talk) 04:24, 15 June 2011 (UTC)

Do you know what the relationship between a corepressor and transrepression is? Does the latter only refer to proteins that repress other proteins, and the first to small molecules as well? Or what? --ἀνυπόδητος (talk) 13:30, 15 June 2011 (UTC)

As far as I am aware, transrepression only refers to proteins that repress other proteins whereas a corepressor could be a protein or a small molecule. However based on a very recent paper (PMID 21496643), the current definition in the transrepression article probably needs to be extended. The current definition describes a "tethering" transrepression (GR → NF-κB → DNA response element) whereas the Chambon paper demonstrates that the glucocorticoid receptor can directly repress gene activity (e.g., GR → DNA response element). In other words, a protein can directly repress a gene. In a way, this is nothing new since this is what prokaryotic repressors do, and for that matter what NF-κB does in the presence of GR. Nevertheless the transrepression definition as currently defined in the article needs to be tweaked. Boghog (talk) 17:20, 15 June 2011 (UTC)

I just noticed your excellent edits that go a long way to fix my horrible translation. I realize this takes work and I am deeply appreciative of your efforts. I will keep my fingers crossed that the German Wikipedia will see fit to keep the article. Again, thanks for your help. Cheers. Boghog (talk) 18:41, 15 June 2011 (UTC)

My pleasure. It was instructive, biochemically as well as linguistically, and you've done quite a few things for me in the past :-)

Regarding transrepression: To me this looks like GCs meet the definition of a corepressor, no? Should the two articles be merged or at least interlinked? (But I'd rather leave that to you; my biochemistry knowledge is rather patchy.) --ἀνυπόδητος (talk) 09:36, 16 June 2011 (UTC)

A barnstar for you!

	The Anti-Vandalism Barnstar
	For your tireless anti-vandalism reverts! Fewq567 (talk) 07:51, 1 July 2011 (UTC)

Thanks! ἀνυπόδητος (talk) 14:56, 1 July 2011 (UTC)

progressive autonomy

I appreciate that you have just shown me the way at fen-phen and think I that can only learn by doing what you say. We had a saying at medical school about procedures:

• • Watch one, do one, teach the third."

PietrH (talk) 01:23, 6 July 2011 (UTC) PietrH (talk) 01:23, 6 July 2011 (UTC)

You're very welcome. Feel free to ask again if you need help. Cheers, ἀνυπόδητος (talk) 13:11, 6 July 2011 (UTC)

DYK for Olaflur

Panyd^{The muffin is not subtle} 09:33, 31 July 2011 (UTC)

DYK for Pentoxyverine

Panyd^{The muffin is not subtle} 16:03, 4 August 2011 (UTC)

Re: EMEA

I will probably go ahead and undo my edits and try a second time. Thanks for the heads up. --User:Woohookitty ^{Disamming fool!} 04:31, 22 September 2011 (UTC)

Survey for new page patrollers

New page patrol – Survey Invitation Hello Anypodetos/Archive 3! The WMF is currently developing new tools to make new page patrolling much easier. Whether you have patrolled many pages or only a few, we now need to know about your experience. The survey takes only 6 minutes, and the information you provide will not be shared with third parties other than to assist us in analyzing the results of the survey; the WMF will not use the information to identify you. If this invitation also appears on other accounts you may have, please complete the survey once only. If this has been sent to you in error and you have never patrolled new pages, please ignore it. Please click HERE to take part. Many thanks in advance for providing this essential feedback. You are receiving this invitation because you have patrolled new pages. For more information, please see NPP Survey

Delivered by MessageDeliveryBot on behalf of Wiki Media Foundation at 11:12, 25 October 2011 (UTC).

We call it chloramine-T

Hi there again. Chemists, the main consumers of this material, call this stuff chloramine-T, not some complicated amide nomenclature created by big brother! Please revert and run the redirect the other way. Yikes (and thanks).--Smokefoot (talk) 21:30, 6 November 2011 (UTC)

Ok, will do. Just let me add a few things first. --ἀνυπόδητος (talk) 21:33, 6 November 2011 (UTC)

Google books entry: Antikörpermimetikum

Did you already see this? Best wishes --Sven Jähnichen (talk) 13:15, 22 November 2011 (UTC)

Cool :-) --ἀνυπόδητος (talk) 19:10, 22 November 2011 (UTC)

Top importance defined..

I propose we use the same classification as others "Subject is extremely important, even crucial, to pharmacology. Strong interest from non-professionals around the world. Usually a large subject with many associated sub-articles. Less than 1% of pharmacy-related articles achieve this rating." Thus well INN is of interest to many I doubt it is generally interesting. --Doc James (talk · contribs · email) 11:53, 25 November 2011 (UTC)

Brought up at Wikipedia talk:WikiProject Pharmacology#Assessment. --ἀνυπόδητος (talk) 14:17, 25 November 2011 (UTC)

Thxs --Doc James (talk · contribs · email) 14:27, 25 November 2011 (UTC)

Disambiguation link notification

Hi. In Lebrikizumab, you recently added a link to the disambiguation page Proliferation (check to confirm | fix with Dab solver). Such links are almost always unintended, since a disambiguation page is merely a list of "Did you mean..." article titles. Read the FAQ • Join us at the DPL WikiProject.

It's OK to remove this message. Also, to stop receiving these messages, follow these opt-out instructions. Thanks, DPL bot (talk) 10:35, 16 December 2011 (UTC)

 Done --ἀνυπόδητος (talk) 11:36, 16 December 2011 (UTC)

Archive 1

Archive 2

Archive 3

Archive 4

Archive 5

→

Archive 10